# Oric Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Oric Pharmaceuticals, Inc.). ## Overview ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance. Its pipeline centers on oncology programs in hormone-dependent cancers, precision oncology, and key tumor dependencies, with development activities run from its South San Francisco headquarters. ## Products & services • ORIC-944: PRC2/EED allosteric inhibitor for resistant prostate cancer • ORIC-114: precision oncology program targeting resistant mutations • ORIC-533: investigational therapy for multiple myeloma • In-licensed oncology drug development programs • Preclinical and clinical-stage cancer drug discovery - **Clinical-stage oncology programs** (100%) — Investigational drug candidates in human clinical trials for cancer. - **Preclinical discovery pipeline** (0%) — Earlier-stage internal and in-licensed programs aimed at resistance mechanisms. - ORIC-944: PRC2/EED allosteric inhibitor for resistant prostate cancer - ORIC-114: precision oncology program targeting resistant mutations - ORIC-533: investigational therapy for multiple myeloma - In-licensed oncology drug development programs - Preclinical and clinical-stage cancer drug discovery ## Customers ORIC does not sell commercial products today; its direct counterparties are clinical trial sites, research collaborators, licensors, and contract service providers that support drug development. If approved in the future, its end customers would be patients treated by oncologists and the healthcare systems that reimburse specialty cancer medicines. - **Clinical trial collaborators** (primary) — Hospitals, investigators, and research networks that enroll patients and run ORIC-sponsored studies. - **Pharmaceutical partners** (primary) — Companies such as Johnson & Johnson and Bayer that supply combination agents and support studies. - **Licensors and biotech counterparties** (secondary) — Owners of external programs that ORIC in-licenses to expand its pipeline. - **Future oncology patients** (emerging) — Patients with resistant cancers who would use ORIC therapies if approved. - Clinical trial investigators and sites running oncology studies - Pharma partners supplying combination drugs for trials - Licensors and biotech partners providing in-licensed programs - Future end users: cancer patients treated by oncologists - Future payers: hospitals, specialty pharmacies, and insurers ## Geography ORIC is headquartered in South San Francisco, California and operates as a U.S.-based development company. Its business is primarily tied to U.S. clinical development, regulatory review, and collaboration with global pharmaceutical partners, while future commercialization would likely extend into major oncology markets outside the United States if products are approved. - Headquartered in South San Francisco, California - Clinical development and regulatory work are centered in the United States - Trials may enroll patients across multiple countries and sites - Future commercialization would depend on oncology markets in North America and abroad ## Strategy ORIC’s strategy is to concentrate resources on a small number of differentiated oncology assets, especially ORIC-944 and ORIC-114, where it believes resistance biology can create clinical value. It also uses business development to add external programs and partnerships, while leveraging combination studies to strengthen the development path for its lead candidates. - **Advance ORIC-944 through late-stage development** (short-term) — This is a lead asset in resistant prostate cancer and a core value driver. - **Develop ORIC-114 as a precision oncology program** (medium-term) — It broadens the pipeline beyond hormone-dependent cancers and targets resistant mutations. - **Use business development to expand the pipeline** (medium-term) — External innovation can add assets without relying only on internal discovery. - Focus development resources on ORIC-944 and ORIC-114 - Use combination trials to improve clinical differentiation - Expand the pipeline through in-licensing and acquisitions - Pursue partnerships to extend programs like ORIC-533 - Build capabilities needed for eventual commercialization ## Risks ORIC is a clinical-stage company with no commercial revenue, so its value depends heavily on successful clinical development, regulatory approval, and future financing. Its programs face the usual oncology risks of trial failure, safety issues, competition, and dependence on third-party collaborators, suppliers, and licensors. - **Clinical development failure** [critical] — Lead programs may not demonstrate sufficient safety or efficacy in trials. - **Capital dependence** [critical] — The company has no revenue and must fund long development timelines. - **Third-party reliance** [high] — Trials, manufacturing, and combination studies depend on external partners and suppliers. - **Competitive pressure** [high] — Large oncology companies can move faster, fund more studies, and reach patients sooner. - No product revenue until a candidate is approved and commercialized - Clinical trials may fail to show safety or efficacy - Dependence on third-party suppliers, CROs, and collaborators - Competition from larger oncology companies with more resources - Need for substantial additional capital to fund development ## Accounting The main accounting issue for ORIC is that research and development spending is expensed as incurred, so reported losses are driven by clinical activity and program mix rather than product sales. Because the company has no revenue, investors should also watch estimates tied to stock-based compensation, collaboration arrangements, and the valuation of investments and cash equivalents. - **Research and development expense recognition** — Affects operating loss and comparability across periods - **Stock-based compensation** — Affects operating expenses and net loss - **Clinical trial accruals** — Affects R&D expense timing - **Investment valuation and maturities** — Affects balance sheet and other income - R&D is expensed as incurred, affecting reported operating losses - No product revenue yet, so collaboration timing would matter if it begins - Stock-based compensation can materially affect operating expenses - Investment maturities and fair value affect cash and interest income - Clinical trial accruals and vendor estimates can shift period expenses --- *Last updated: 2026-04-29T04:44:25.308047+00:00*